GlassScriptPhysician profile
Oon Leedhanachoke
NPI 1578520482
$4,714.50
in general payments reported to CMS, 2019-2025
42 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $219 · 2021: $474 · 2022: $681 · 2023: $613 · 2024: $946 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,264.23 | 2019-2025 | |
| Janssen Biotech, INC. | $650.07 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $315.51 | 2019-2025 | Eohilia, Gattex |
| Urogen Pharma, INC. | $230.18 | 2024-2025 | |
| Daiichi Sankyo INC. | $221.45 | 2019-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $212.74 | 2019-2024 | Dificid |
| Covidien LP | $179.29 | 2019 | |
| Intercept Pharmaceuticals, INC. | $157.15 | 2019-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $151.00 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.21 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $126.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $114.23 | 2023-2025 | Watchman Access System, Watchman Flx, Axonics |
| Ardelyx, INC. | $101.79 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $96.83 | 2023-2024 | Omvoh |
| Edap Technomed INC | $93.00 | 2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oon Leedhanachoke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.